Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psychiatry Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psychiatry Other
    Asenapine, Olanzapine Effective in Patients With Bipolar 1 Disorder: Presented at WCBP - (DGDispatch)
    FDA: Boxed Warning Required for Varenicline, Buproprion Due to Risk of Suicidal Behaviour - (DGNews)
    Quetiapine Monotherapy Shows Potential in Post-Traumatic Stress Disorder: Presented at WCBP - (DGDispatch)
    Olanzapine Effective for Bipolar Disorder in Naturalistic Setting: Presented at WCBP - (DGDispatch)
    Study Suggests Irritability Should Be Considered When Diagnosing Bipolar Disorder in Children - (DGNews)

    News archive

     Recent webcasts/CME - Psychiatry Other
      A Guide to Advances in Pain Management: A Synopsis of Roundtable Discussions
      Recognizing and Managing Psychotic and Mood Disorders in Primary Care
      Challenges of the Comorbid Patient: Evaluating Common Comorbidities in Adults and Children/Adolescents and Treatment Considerations
      Mixed States: Practical Application of Evidence, Guidelines, and Clinical Judgment
      Hypomania: The Clinical Reality of Diagnosing Adult and Child/Adolescent Patients

      Webcasts/CME archive

       Recent cases - Psychiatry Other
        Female Sexual Dysfunction as a Comorbid Illness
        11p Microdeletion Including WT1 but not PAX6, Presenting with Cataract, Mental Retardation, Genital Abnormalities and Seizures: Case Report
        Comorbidity of Asperger's Syndrome and Bipolar Disorder
        Psychiatric Disorder Associated with Vacuum-Assisted Breast Biopsy Clip Placement: A Case Report
        Treating Bipolar Disorder in Patients with Renal Failure Having Haemodialysis: Two Case Reports

        Cases archive
          




        my personal edition > psychiatry other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Atypical Antipsychotics Address Psychotic Symptoms in Paediatric Bipolar Disorder: Presented at AACAP

        By Paula Moyer

        MIAMI BEACH, FL -- October 27, 2003 -- Treatment of paediatric bipolar disorder with atypical antipsychotics such as risperidone (Risperdal) and olanzapine (Zyprexa) stabilizes mood and reduces psychotic symptoms, according to findings presented here October 17th at the 50th Anniversary Meeting of the American Academy of Child and Adolescent Psychiatry.

        "Both of the atypical antipsychotic agents we used in this open trial were effective at reducing psychotic symptoms," said Erick Mick, ScD, a psychometrician, Pediatric Psychopharmacology Research Unit, Massachusetts General Hospital, in Boston, Massachusetts, Massachusetts.

        To determine if there were any secondary benefits to treatment with atypical antipsychotics, particularly regarding psychotic behavior, in children and adolescents with early-onset bipolar disorder, Dr. Mick and colleagues conducted an 8-week study with 30 boys and 18 girls with bipolar disorder with manic episodes.

        Patients were an average of 8.9 years old, 13 boys and 5 girls were treated with olanzapine, and 17 boys and 13 girls were treated with risperidone.

        The investigators evaluated the patients' psychotic symptoms with the Brief Psychiatric Rating Scale (BPRS) and documented the medications' short-term efficacy and safety, as well as the time course to response.

        They also documented a statistically significant reduction, averaging 12 points, on the BPRS at the end of the study compared to the baseline scores (F[2,119]= 34.1, P < .0001). There was no statistically significant difference in scores between patients treated with risperidone and those treated with olanzapine (t = -0.45, P = .6).

        However, Dr. Mick said that a preliminary evaluation showed that the risperidone group had significant improvements in three subscales of the BPRS: thought disorder, anxiety/depression, and hostility (P < .001, P < .009, and P < .001, respectively).

        However, Dr. Mick cautioned that the data are highly preliminary. Therefore, he suggested that investigators develop controlled studies that target more specifically the psychotic component of early-onset bipolar disorder.


        [Study title: Treatment of Psychotic Symptoms in Children With Bipolar Disorder. Abstract C36]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send